NYSE:ANRO

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

Retrieved on: 
星期三, 五月 29, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Conference, Neuroscience

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York.
  • Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Thursday, June 6, 2024, at 2:30 p.m.
  • ET, and management will host one-on-one meetings with investors.
  • A live webcast of the fireside chat will be available on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the conclusion of the event.

Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

Retrieved on: 
星期二, 五月 21, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Business administration, Horizon Therapeutics, Kellogg School, Marketing, University, Head, Horizon, Mental health, Psychiatry, Epilepsy, Sleep, Neuroscience, CNS, DSM-IV codes, Alto, SVKM's NMIMS, Schizophrenia, ALS, Northwestern University, Vortioxetine, Aripiprazole, Management

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO).

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO).
  • Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies.
  • “Mike has dedicated his career to leading the product life cycle for companies in CNS and psychiatry, from early-stage planning and portfolio strategy through launch and brand management,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto.
  • At Alto we aim to develop each of our programs based on sound scientific, strategic, and commercial considerations; we believe adding Mike to the team at this juncture will further our ability to do this across our broad pipeline.”
    Prior to joining Alto, Mr. Hanley served as chief commercial officer and chief business officer at Aeglea BioTherapeutics.

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
星期二, 五月 14, 2024
Mental Health, Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, CIAS, PET, Partnership, Patient, PDE4, Human, EEG, MDD, Central nervous system disease, Depression, Overalls, Safety, NMDA, Dopamine, Neuroscience, CNS, DSM-IV codes, Brain, Society, Psychopharmacology, Research, Schizophrenia, Anhedonia, Cognition, Histamine, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by a memory-based cognitive biomarker.
  • Enrollment is ongoing and the Company expects to report topline data in the second half of 2024.
  • Net Loss: The Company incurred a net loss of $13.4 million for the quarter ended March 31, 2024, as compared to $7.3 million for the quarter ended March 31, 2023.

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

Retrieved on: 
星期四, 五月 9, 2024
Neurology, Mental Health, Health, Pharmaceutical, Clinical Trials, Schizophrenia, CMO, Neuroscience, University of Toronto, University of California, Cognition, Vortioxetine, Biological Psychiatry (journal), Biomarker, Prevalence, Into, Diagnosis, Deficit spending, Drug development, Area studies, Remind, Depression, Data, Pharmacodynamics, EEG, Bipolar, Trial, Chair, Volunteering, Lab, Cognitive deficit, Doctor of Philosophy, Society, University, Cyclothymia, Randomness, ASCP, Pharmaceutical industry

“Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.

Key Points: 
  • “Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.
  • Importantly, we have systematically identified and prospectively replicated neurobiological markers linked to cognitive impairment associated with schizophrenia in a comprehensive analysis inclusive of all major candidate biomarkers.
  • New analysis of vortioxetine Phase 3 data demonstrates that baseline cognitive performance is not a moderator of response to vortioxetine.
  • A notable relationship between theta response and processing speed, which is thought to underpin cognitive impairment in schizophrenia, was observed.

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

Retrieved on: 
星期二, 四月 23, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Volunteering, CIAS, TDS, Safety, Pharmacokinetics, Neuroscience, Partnership, PDE4, Schizophrenia, Therapy, Patient, Multimedia, AUC, Absorption, Plasma, Deficit spending, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).
  • (Graphic: Alto Neuroscience, Inc.)
    “These positive results provide a strong indication that ALTO-101 could become an important therapeutic option for a broad range of indications,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.
  • “Oral PDE4 inhibitors have shown promise as pro-cognitive therapeutics but are associated with burdensome and dose-limiting side effects.
  • Despite these dosing and tolerability challenges, PDE4 inhibitors are used widely in other non-CNS indications, often with sub-optimal dosing regimens.

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Retrieved on: 
星期三, 四月 3, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Alertness, Depression, EEG, Motivation, ClinicalTrials.gov, MDD, Patient, Neuroscience, Anhedonia, H3, Pleasure, Alto, Cognition, Safety, Pharmacokinetics, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.
  • The present study will evaluate these effects in patients with MDD to determine the potential of ALTO-203 as an antidepressant.
  • “In a Phase 1 study, ALTO-203 demonstrated an acute increase in positive emotion relative to placebo and across several dosage levels.
  • This Phase 2 study consists of two sequential double-blind, placebo-controlled treatment periods and examines two doses of ALTO-203 and placebo given as monotherapy in patients with MDD.

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期四, 三月 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

Retrieved on: 
星期一, 三月 11, 2024
Mental Health, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Internal medicine, Psychiatry, Caregiver, Physician, Diabetes, Patient, Neuroscience, Bristol Myers Squibb, Maha, Bioverativ, UnitedHealth Group, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D.
  • to the company’s board of directors.
  • “Maha joins our Board at a pivotal moment for Alto, as we continue on our path and fulfill our ambition of redefining psychiatry with our precision pipeline in areas of persistent medical need,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto.
  • “Throughout her distinguished career, Maha has been dedicated to advancing patient care through more personalized approaches to treatment.

Alto Neuroscience to Participate in Upcoming Investor Conferences

Retrieved on: 
星期四, 三月 7, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Neuroscience, Alto

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences:

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences:
    Jefferies Biotech on the Bay Summit, March 12-13th: Alto management will participate in one-on-one meetings with investors during the conference.
  • UBS Virtual CNS Day, March 18th: Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Monday, March 18, 2024, at 2:30 pm ET.
  • Stifel 2024 Virtual CNS Days, March 19-20th: Dr. Etkin will participate in a fireside chat on Wednesday, March 20, 2024, at 11:30 am ET.
  • Alto management will also participate in one-on-one meetings with investors during the conference.

Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference

Retrieved on: 
星期二, 二月 27, 2024
Health, Communications, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Public Relations, Investor Relations, Neuroscience, Conference

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET.
  • The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available for 90 days following the presentation.